Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive oxcarbazepine extended‑release for refractory partial-onset seizures
2008-003333-25Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxcarbazepine in epilepsy (3 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Percentage change in partial seizure frequency per 28 days during Treatment Phase. Started Aug 2009; status: completed.
02
Drugs
oxcarbazepine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2008-003333-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003333-25.